Correction to: Cancer Gene Therapy (2021) 29:875–878 https://doi.org/10.1038/s41417-021-00383-9, published online 01 September 2021
in the 3rd paragraph, 6th sentence of the Introduction, “Compared with the wild-type, the KRAS mutation disrupts the guanine exchange cycle, thereby locking it in an inactive GDP-bound form that drives pro-tumorigenic signals [18] (Fig. 1b).”
Should be changed to:
“Compared with the wild-type, the KRAS mutation disrupts the guanine exchange cycle, thereby locking it in an active GTP-bound form that drives pro-tumorigenic signals [18] (Fig. 1b).”
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, J., Kang, R. & Tang, D. Correction: The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther 30, 1715 (2023). https://doi.org/10.1038/s41417-023-00692-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41417-023-00692-1
